BMI-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 340-344

  Tong, Yong Qing ^a   Liu, Bei ^a   Huang, Jian ^a   Liu, Yan ^a   Guo, Feng Jie ^a   Zhou, Guo Hua ^a   Xie, Ping Li ^a   Li, Yue Hui ^a   Hu, Jin Yue ^a   Li, Guan Cheng ^a  

^a Central South University   (China)

Author keywords

Autoantibody; Biomarker; BMI 1; Early diagnosis; Nasopharyngeal carcinoma

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; BMI1 PROTEIN; COMPLEMENTARY DNA; MESSENGER RNA;

ADULT; AGED; ARTICLE; BACTERIOPHAGE T7; CELL STRAIN K 562; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODETECTION; MALE; NASOPHARYNX CARCINOMA; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SERUM;

EID: 45349091149     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5422     Document Type: Article

References (31)

1. Haupt Y, Bath ML, Harris AW, Adams JM: bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 1993; 8:3161-4.
2. Alkema MJ, van der Lugt NM, Bobeldijk RC, Berns A, van Lohuizen M: Transformation of axial skeleton due to overexpression of bmi-1 in transgenic mice. Nature 1995; 374:724-7.
3. Iwama A, Oguro H, Negishi M, Kato Y, Nakauchia H: Epigenetic regulation of hematopoietic stem cell self-renewal by polycomb group genes. Int J Hematol 2005; 81:294-300.
4. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ: MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci USA 2003; 100:8342-7.
5. Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE, Amin HM, Ward DC, Ma Y: Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci USA 2007; 104:10494-9.
6. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001; 97:3896-901.
7. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A: Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 2007; 21:1116-22.
8. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001; 84:1372-6.
9. Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL, van Lohuizen M, Colomer D, Campo E: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001; 61:2409-12.
10. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004; 203:217-24.
11. Dal Maso L, Zucchetto A, La Vecchia C, Montella M, Conti E, Canzonieri V, Talamini R, Tavani A, Negri E, Garbeglio A, Franceschi S: Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br J Cancer 2004; 90:2176-80.
12. Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, Diaz R, Lorenzo Y, Hurtado A, Sanchez A, Bonilla F: Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res 2007; 9:R55.
13. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A: Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 2007; 21:1116-22.
14. Cui H, Hu B, Li T, Ma J, Alam G, Gunning WT, Ding HF: Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007; 170:1370-8.
15. Raaphorst FM, Otte AP, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Meijer CJ: Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation, J Immunol 2001; 166:5925-34.
16. Raaphorst FM, van Kemenade FJ, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ: Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol 2000; 164:1-4.
17. Steele JC, Torr EE, Noakes KL, Kalk E, Moss PA, Reynolds GM, Hubscher SG, van Lohuizen M, Adams DH, Young LS: The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 2006; 95:1202-11.
18. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66:6225-32.
19. Cho WC, Yip TT, Ngan RK, Yip TT, Podust VN, Yip C, Yiu HH, Yip V, Cheng WW, Ma VW, Law SC: ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin Chem 2007; 53:241-50.
20. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L: The case for early detection. Nat Rev Cancer 2003; 3:243-52.
21. Smith RA, Cokkinides V, Eyre HJ: American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2006; 56:11-25.
22. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM: Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353:1224-35.
23. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB: Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 2003; 63:7365-76.
24. Fernández-Madrid F, Tang N, Alansari H, Granda JL, Tait L, Amirikia KC, Moroianu M, Wang X, Karvonen RL:. Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer. Cancer Res 2004; 64:5089-96.
25. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM: Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004; 10:4427-36.
26. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC: Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 2005; 96:77-83.
27. Wu CC, Chien KY, Tsang NM, Chang KP, Hao SP, Tsao CH, Chang YS, Yu JS: Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005; 5:3173-82.
28. Ou SH, Zell JA, Ziogas A, Anton-Culver H: Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol 2007; 18:29-35.
29. Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:1765-77.
30. Buccheri GF, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola F: Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 1986; 57:2389-96.
31. Wu GP, Ba J, Zhao YJ, Wang EH. Diagnostic value of CEA: CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer. Acta Cytol 2007; 51:679-80.